FLT3 and acute myeloid leukemia: Other ongoing studies are evaluating venetoclax + quizartinib (NCT03735875) and venetoclax + HMA + FLT3 TKI in FLT3-mutated relapsed/refractory AML (NCT03661307) and in newly diagnosed AML ineligible to intensive chemotherapy (NCT04140487).